Logotype for Iovance Biotherapeutics Inc

Iovance Biotherapeutics (IOVA) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Iovance Biotherapeutics Inc

Q3 2026 earnings summary

10 Nov, 2026

Executive summary

  • Q3 product revenue reached $121.469M, up 80% YoY; gross margin was a quarterly record of ~60%.

  • More than 1,000 U.S. commercial patients had received Amtagvi, and the authorized treatment-center network exceeded 100.

  • FY2026 revenue guidance remained $410M–$420M as registrational TIL programs advanced in NSCLC, sarcoma and melanoma.

Financial highlights

  • Q3 product revenue was $121.469M vs. $67.455M; 9M revenue was $292.212M vs. $176.731M.

  • Q3 net loss narrowed to $22.271M from $91.253M; diluted loss per share was $0.05 vs. $0.25.

  • Q3 operating loss was $23.968M vs. $94.901M; 9M operating loss was $156.916M vs. $329.896M.

  • Q3 R&D expense was $49.337M, down ~16% QoQ; SG&A was $38.6M.

Outlook and guidance

  • FY2026 product revenue guidance remained $410M–$420M; Q4 sequential revenue growth was expected.

  • Management expected cash runway well into 2029; the financial statements assessed available capital as sufficient for planned costs for at least 12 months after issuance.

  • IOV-LUN-202 Cohorts 1 and 2, targeting ~80 patients, were completing enrollment; a lifileucel sBLA was planned for 2027, subject to FDA discussions and review.

  • POSITILITY began enrollment in November 2026 with an 80-patient target; OPTILISM frontline biomarker-enriched NSCLC was planned for 2027.

  • Potential UK and Swiss Amtagvi approvals were expected in Q1 2027; EU application resubmission was planned for 2027.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Iovance Biotherapeutics